Macsita-MXR 50/500 Tablet is a combination oral antihyperglycemic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the body's incretin system, increasing insulin release and decreasing glucagon levels in a glucose-dependent manner, thereby improving glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The synergistic action of these two agents provides effective glycemic regulation in patients inadequately controlled by diet and exercise alone. Macsita-MXR 50/500 is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with renal impairment, metabolic acidosis, or known hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish with continued use. Regular monitoring of renal function and glycemic parameters is recommended during therapy. This combination tablet offers a convenient dosing option, improving patient adherence and optimizing therapeutic outcomes in type 2 diabetes management.